The Clinical Pathways Congress will occur from October 26–28, 2018 at the Westin Waterfront Boston in Boston, MA. A question-and-answer session with the faculty will follow each presentation.
To be eligible for documentation of credit, participants must complete the online evaluation form at www.naccme.com. All individuals who participate in the conference and submit the completed evaluation form online may immediately print their documentation of credit.
For questions regarding this educational activity, please call 609.371.1137. See the registration rates section of the website for fee information.
Please note that the cutoff date for cancellation is September 10, 2018. All cancellations must be received in writing and postmarked by that date. Full registration (less a $100 processing fee or full registration amount, whichever is less) will be refunded only to cancellations received in writing before that date. No refunds will be issued after September 10, 2018. Registrations are transferable at any time.
After attending the Clinical Pathways Congress 2018 meeting, participants should be able to:
• Outline the opportunities and challenges associated with using clinical pathways as a foundation for value-based care.
• Examine the roles and responsibilities of payers, providers, and pathway developers in creating and implementing clinical pathways.
• Contribute to the effective implementation of clinical pathways to optimize quality of care, cost efficiency, and health outcomes.
This activity is designed for directors of oncology practice programs and cancer centers, oncologists, hematologists, commercial and government payers, pathway development executives, reimbursement specialists, specialty pharmacists, HEOR specialists, and other healthcare professionals interested in learning how to implement, integrate, and measure treatment pathways.
In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
NACCME designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity awards 12.50 contact hours.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.50 contact hours.
This activity is approved for 12.50 contact hours (0.1250CEU) of continuing pharmacy education. (UAN J0006201-0000-18-003-L01-P)
Additional UANs to be determined.
Each of these educational activities is a knowledge-based activity.
ACPE Credit Policy
Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.
Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.
*Contact hours subject to change.
North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609.371.1137.
Copyright ©2018 by North American Center for Continuing Medical Education, LLC. All rights reserved.
Clinical Pathways Congress is supported in part by educational grants from AstraZeneca, Celgene, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Seattle Genetics, and TESARO, Inc.